Search This Blog

Monday, April 5, 2021

Only immunised pilgrims allowed to Mecca during Ramadan, say Saudis

 Saudi authorities said Monday only people immunised against Covid-19 will be allowed to perform the year-round umrah pilgrimage from the start of Ramadan, the holy fasting month for Muslims. 

The hajj and umrah ministry said in a statement that three categories of people would be considered "immunised" -- those who have received two doses of the vaccine, those administered a single dose at least 14 days prior, and people who have recovered from the infection.

Only those people will be eligible for permits to perform umrah, as well as to attend prayers in the Grand Mosque in the holy city of Mecca.

It added that the condition also applies for entry into the Prophet's Mosque in the holy city of Medina.

The ministry said the policy starts with Ramadan, which is due to begin later this month, but it was unclear how long it would last.

It was also not clear whether the policy, which comes amid an uptick in coronavirus infections in the kingdom, would be extended to the annual hajj pilgrimage later this year.

Saudi Arabia has reported more than 393,000 coronavirus infections and 6,700 deaths from Covid-19.

 The kingdom's health ministry said it has administered more than five million coronavirus vaccines, in a country with a population of over 34 million.

 Last month, King Salman replaced the hajj minister, months after the kingdom hosted the smallest hajj in modern history due to the pandemic.

Mohammad Benten was relieved from his post and replaced by Essam bin Saeed, according to a royal decree published by official Saudi Press Agency (SPA).

The kingdom hosted the hajj in late July last year.

Only 10,000 Muslim residents of Saudi Arabia itself were allowed to take part, a far cry from the 2.5 million Muslims from around the world who participated in 2019.

It is unclear how many pilgrims will be allowed for hajj this year.

According to the pro-government Okaz newspaper, only vaccinated pilgrims will likely be permitted this year.

In a relaxation of coronavirus curbs last October, Saudi Arabia opened the Grand Mosque for prayers for the first time in seven months and partially resumed the umrah pilgrimage.

The umrah usually attracts millions of Muslims from across the globe each year.

Authorities said the umrah will be allowed to return to full capacity once the threat of the pandemic has abated.

https://www.france24.com/en/middle-east/20210405-only-immunised-pilgrims-allowed-to-mecca-during-ramadan-say-saudis

23% Gen Z, millennial adults say they will never get covid vax

 As the vaccine rolls out, so too do opinions causing more youth to speak out about whether or not they will get the COVID-19 shot. One survey by NBCLX and Morning Consult in March 2021 showed 23 percent of Generation Z and millennial adults ages 18 through 34 said they would never get the vaccine.

The Lexington-Fayette County Health Department said having the youth vaccinate is crucial for herd immunity.

"For our younger population, the people who feel like this might not affect them or it's not as serious for them, it is," LFCHD Communications Director Kevin Hall said. "Think about your parents. Think about your grandparents that you can carry this to them and make them very sick, cause them, unfortunately, to die from this because people have 70 and older in Lexington, in Kentucky are the ones most at risk for death."

Hall said receiving the shot will be of benefit to young people beyond protection.

"This will help us open up restaurants, businesses, it will help people get to ballgames, this spring, the summer; the fall," Hall said. "This will make things back to how it was in some sense, pre-pandemic."

Freshman University of Kentucky student Izzy Davis said although she would be willing to get the shot, she knew people who were far more hesitant.

"Some people who have already had COVID are a little bit reluctant to get it because they feel like they're immune now that they've had it, so they don't see the point in getting the vaccine," Davis said.

Overall, though she said she was surprised how many people she knew who already got it.

"I think that just shows our eagerness, as a University to get back to normal," said Davis. "We'll all do it eventually it's just a matter of getting the ball rolling."

One UK senior, Eleni Digens, said she already got her shot and would not be upset if UK required it to go to school in-person.

"I think that's understandable, you know, given this pandemic, and we're all trying to get out of it as quick as possible so, you know, we have the cure here and, you know, if we have the available dosages then, yeah, I think making it a requirement would be a good thing," said Digens.

Davis said if push came to shove, she thinks her freshman peers would also oblige to the shot.

"I think people might moan about it under their breath but in all reality, we just want to get back to normal, especially people in my position as freshmen who haven't had a college experience," explained Davis. "We'll do anything to get back to normal and be able to have what everybody else has been able to have."

Hall said, unlike other pandemics, the coronavirus pandemic has an extra hurdle: the internet.

"If you look at the 1918 Influenza outbreak, that's compared to a quite a bit from public health experts but this is so different in the sense of, now you have social media and the people who are opposed to vaccines or don't believe that COVID-19 is even an issue who are spreading misinformation on a daily basis wide and far," stated Hall. "So, we have to really increase our efforts as part of the 'LEX Do This' campaigns to let people know that this is safe, it is effective that you need to get shot in order to stay protected."

"We'll all do it eventually it's just a matter of getting the ball rolling," said Davis.

The U.S. Food and Drug Administration approved ages 16 and up to receive the Pfizer vaccine and 18 and up to receive the Moderna vaccination.

As of Monday, the Lexington-Fayette County Health Department noted they only distribute the Moderna vaccine but have many slots open to vaccinate Lexingtonians.

https://www.lex18.com/news/coronavirus/study-23-gen-z-millennial-adults-say-they-will-never-get-the-vaccine

COVID-19 hospitalizations in Texas continue to decline

 The count of people hospitalized with COVID-19 in Texas has continued to decline, even as state health official reported more than 1,600 new cases of the disease caused by the novel coronavirus Sunday.

The Texas Department of State Health Services reported 21 new fatalities from COVID-19 Sunday along with 1,465 confirmed cases of the virus and 219 probable cases.

There were 2,817 people in state hospitals with the disease Saturday, the most recent day for which data is available. That's fewest since June of last year.

The lower hospitalization count comes as more than 15% of Texans have been fully vaccinated, according to Johns Hopkins University data. The federal Centers for Disease Control reports 27% of the state's population has received at least one dose

Around one in twenty coronavirus tests administered in Texas over the last week have come back positive, according to the university data.

Texas is set to receive 2.5 million more doses of coronavirus vaccines this week, according to state health officials. All Texans 16 and older are eligible to receive the vaccine.

https://wset.com/news/coronavirus/covid-19-hospitalizations-in-texas-continue-to-decline

Pfizer halts corona vaccine shipments to Israel after country fails to pay

 Pfizer has halted shipments of coronavirus vaccines to Israel in outrage over the country failing to transfer payment for the last 2.5 million doses it supplied to the country, The Jerusalem Post has learned.

Senior officials at Pfizer have said they are concerned that the government-in-transition will not pay up and the company does not want to be taken advantage of. They said that they do not understand how such a situation can occur in an organized country.

Army Radio reported that Pfizer called Israel a “banana republic.”
A shipment of 700,000 doses was expected to arrive in Israel on Sunday but was delayed until further notice.
Pfizer told the Post that the company has completed all deliveries to Israel under its initial agreement to provide its COVID-19 vaccine, signed in November 2020.
"The company is currently working with the Israeli government to update the agreement, to supply additional vaccines to the country. While this work continues, shipments may be adjusted," the company said in a statement.
The Health Ministry would not comment on the statement. 

Israel paid for the first 10 million vaccines it received to manage the majority of its mass vaccination campaign. But when Israel started to run short in February, an agreement was made between Prime Minister Benjamin Netanyahu and Pfizer CEO Albert Bourla to supply the country with the additional doses it needed.
The Post was informed that the government never paid for the last 2.5 million.
So far, Israel has spent NIS 2.6 billion on coronavirus vaccines, it was revealed last month at a meeting of the Knesset Finance Committee. In general, the government does not discuss the cost of vaccines due to confidentiality agreements with the companies. It is understood that Israel paid much more per dose than any other country.
The Health Ministry had been putting pressure on the government to approve the purchase of an additional NIS 3.5 billion - more than 30 million vaccines - even before Passover and the government was set to convene last Monday. However, the meeting was postponed indefinitely due to a conflict between Netanyahu and Alternate Prime Minister Benny Gantz.
Gantz canceled the meeting because of Netanyahu’s refusal to approve the permanent appointment of a justice minister. His term as acting justice minister ended on April 2, three months after he took the post in place of Avi Nissenkorn, who had resigned.
A permanent appointment has still not been made.
HEALTH MINISTER Yuli Edelstein spoke with Gantz on Sunday night to try to persuade him of the importance of moving forward with the payment and purchase.
A spokeswoman for Gantz told the Post that "even though the prime minister has done a lot to hurt the functioning of the government," the alternate prime minister will "do nothing that will affect the people of Israel's health by denying the vaccines."
Nonetheless, sources in Gantz’s office stressed that if this meeting is so urgent for Edelstein “all he has to do is call PM Netanyahu and ask him to appoint a justice minister.”
Gantz’s office further claimed that the purchase of the 2.5 million vaccines was already approved and that any delay in payment was on behalf of the Health Ministry. 
The source said the country had already purchased 27 million doses - which includes the Pfizer, Moderna and AstraZeneca vaccines - “that should suffice for the near future.” The source said procurement of additional vaccines further down the line requires due process and deliberation.
Meanwhile, health officials are concerned that Israel will miss its opportunity to purchase the vaccines, which are sought after by countries around the world.
Coronavirus commissioner Prof. Nachman Ash told the Post that if Israel does not speedily sign the necessary contracts, it may not be able to vaccinate its children or provide citizens with booster shots against vaccine-resistant variants, or if immunity wanes.
“There is real competition to buy vaccines by countries around the world,” Ash said in an interview last week. “We want to reserve our place at the top of the list and not be pushed down to the end so that we cannot get them [vaccines] when they are most needed.”
PFIZER ANNOUNCED that its vaccine was safe and effective against the virus for children in this age cohort, and is now seeking FDA approval. Health Ministry Director-General Chezy Levy said over the weekend that Israeli adolescents could be vaccinated as early as May.
The vaccination campaign has enabled Israel to open up its economy over the past month, including sending more children back to school on Monday.
The Health Ministry agreed to allow children in third grade to learn without capsules. Older students are still in capsules, which means that they still cannot go to school full time. 
Ash told Ynet that the ministry wants to monitor whether there is a rise in infection after removing capsules in third grade. If not, then the rest of the country’s elementary school students will be able to study in full within the next two weeks.
The ministry has said it wants to roll out rapid testing for middle school students before allowing them to learn in their regular classrooms.
The Health Ministry reported on Monday that the number of patients in serious condition continued to drop and only 0.6% of the tests performed the day before returned a positive result, marking the lowest rate since May 2020. However, at the same time, the reproduction rate rose to 0.71 - a figure that has not been recorded for a month.
Some 195 new coronavirus cases were identified on Sunday out of 32,886 tested.
Although Israel consistently performs fewer tests on Sundays than other weekdays, the rate of the tests returning positive was the lowest since last May.
Moreover, the number of serious patients dropped to 323. They were 441 on the previous Monday and 543 the week before that.
Some 6,245 people have died of COVID-19 in Israel since the beginning of the pandemic.
The government is expected to convene a special cabinet meeting about the vaccines in the coming days. Sources in the Health Ministry say they are hoping that it won’t be too late.

Pliant Therapeutics started at Buy by Citi

 Target $52

https://finviz.com/quote.ashx?t=PLRX

Illumina Prelim Q1'21 Revenue; Updates Fiscal Year 2021 Revenue Guidance

 Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing adjustments, Illumina expects to report first quarter 2021 revenue of approximately $1,085 million, compared to $859 million in the first quarter of 2020. This represents year-over-year revenue growth of approximately 26% for the quarter. For fiscal year 2021, Illumina now expects year-over-year revenue growth in the range of 25%-28% compared to fiscal year 2020.

The company’s record preliminary revenue in the first quarter of 2021 was driven by:

  • Record orders of approximately $1.4 billion in the quarter and sequencing revenue growth of approximately 28% compared to the prior year period
  • Sequencing consumables growth of approximately 25% compared to the prior year period demonstrating the solid recovery from the COVID-19 pandemic and the strength of our core business. Most customers are now at or above pre-COVID activity levels. COVID-19 surveillance revenues for sequencing consumables were approximately $20 million in the quarter
  • Sequencing instrument growth of approximately 120% compared to the prior year period, reflecting strong performance across all instrument categories. The mid-throughput category achieved another record quarter in placements. Some customers built additional capacity for COVID-19 surveillance work and accelerated instrument purchases, which resulted in approximately $35 million of incremental instrument revenue in the quarter

“Our core business is exceptionally strong and growing ahead of our expectations. This is reflected in our outstanding preliminary first quarter revenue and, as a result, we are raising our 2021 revenue guidance,” said Francis deSouza, President and CEO. “We are seeing broad-based acceleration across our core clinical and research applications as more patients, physicians and researchers than ever access the benefits of next generation sequencing. In addition, we are experiencing increased demand for COVID surveillance globally due to the critical role that Illumina’s next generation sequencing technology plays in the fight against this pandemic.”

The company expects to report its full first quarter 2021 results on its upcoming quarterly conference call following the close of market on Tuesday, April 27, 2021.

https://www.businesswire.com/news/home/20210405005446/en/Illumina-Announces-Preliminary-Revenue-for-First-Quarter-Fiscal-Year-2021

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

 

  • Crossover allows participants to continue in trials and remain blinded
  • Ensures that all trial participants receive active vaccine
  • South Africa and UK crossover arms initiated; US/Mexico PREVENT-19 crossover planned

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company's COVID-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax' Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.

Under Novavax' updated clinical trial protocols[1], all participants in the UK and US Phase 3 trials will be offered the opportunity to receive an additional round of injections. Participants who elect to do so will receive an additional two-dose regimen of either vaccine (for those who originally received placebo) or placebo (for those who originally received vaccine). Participants in the South Africa Phase 2b trial will receive either active vaccine for those who initially received placebo, or a booster dose of active vaccine for those who initially received active vaccine. Participants across all three trials will remain blinded to their courses of treatment to preserve the ability to assess efficacy in each trial, and all will be followed for up to two years to monitor the safety and durability of protection the vaccine. In the trials taking place in South Africa and the United Kingdom, half of the participants initially received the active vaccine while two-thirds of participants in PREVENT-19, the trial being conducted in the US and Mexico, initially received active vaccine.

"The crossover arms ensure that all participants have access to an active vaccine candidate while allowing Novavax to continue to monitor the safety and efficacy of our vaccine over the long term," said Filip Dubovsky, M.D., Chief Medical Officer, Novavax. "We are grateful to the volunteers who stepped forward to take part in our clinical trials, without whom we would be unable to develop, study and ultimately deliver what we hope will be a significant tool in the fight against COVID-19."

The company is also planning a crossover in the PREVENT-19 study, for which the company expects to read out initial clinical data during the second quarter. In addition, the company is planning to expand the trial to include pediatric and adolescent arms, which are also expected to begin in the second quarter.

https://www.prnewswire.com/news-releases/novavax-initiates-covid-19-vaccine-clinical-trial-crossover-301262318.html